View printer-friendly version |
Charles River Expands Strategic Partnership With SAMDI Tech
Provides Greater Access to Label-Free High-Throughput Screening Solutions
The SAMDI technology combines self-assembled monolayers and MALDI MS, and addresses the throughput and sample preparation limitations of traditional MS screening methods.
The combination of Charles River’s end-to-end portfolio and industry-leading scientific bench with SAMDI Tech’s innovative technology and expertise in assay solutions has the potential to significantly accelerate and augment clients’ discovery efforts by measuring biochemical activities and binding events for virtually any target.
Approved Quotes
- “Our collaboration with SAMDI Tech is another step that we’re taking toward accelerating drug discovery and development. By generating quality data faster during hit identification, we can help our clients make critical go/no go decisions earlier in the process, to advance their programs.” –Wilbert Frieling, D.V.M., Corporate Senior Vice President, Global Discovery Services, Charles River
-
“With over a decade of industry experience, SAMDI Tech has a well-respected track record of producing high quality data. We are excited to partner with them to bring this technology to our clients.” –
Julie Frearson , Ph.D., Corporate Senior Vice President, Chief Scientific Officer, Charles River -
“We are excited to expand on our successful partnership with Charles River, whose clients will join our global client base to benefit from our label-free SAMDI technology, which continues to deliver cutting-edge solutions backed by high-quality, data-driven results.” –
Emilio Cordova , PhD, MBA, Chief Executive Officer, SAMDI Tech
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005074/en/
Charles River Investor Contact:
Corporate Vice President, Investor Relations
+1- 781-222-6455
todd.spencer@crl.com
Charles River Media Contact:
Corporate Vice President & Chief Communications Officer
+1-781-222-6168
amy.cianciaruso@crl.com
Source: